Valion Bio (TIVC) Free Cash Flow (2021 - 2025)
Valion Bio has reported Free Cash Flow over the past 5 years, most recently at -$2.3 million for Q4 2025.
- For Q4 2025, Free Cash Flow fell 74.57% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached -$7.0 million, down 22.88%, while the annual FY2025 figure was -$7.0 million, 22.93% down from the prior year.
- Free Cash Flow for Q4 2025 was -$2.3 million at Valion Bio, down from -$2.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$543000.0 in Q2 2021 and troughed at -$2.8 million in Q3 2022.
- A 5-year average of -$1.8 million and a median of -$1.8 million in 2023 define the central range for Free Cash Flow.
- Biggest five-year swings in Free Cash Flow: plummeted 231.73% in 2022 and later surged 49.84% in 2024.
- Year by year, Free Cash Flow stood at -$2.8 million in 2021, then grew by 19.31% to -$2.2 million in 2022, then increased by 20.34% to -$1.8 million in 2023, then rose by 25.31% to -$1.3 million in 2024, then crashed by 74.57% to -$2.3 million in 2025.
- Business Quant data shows Free Cash Flow for TIVC at -$2.3 million in Q4 2025, -$2.0 million in Q3 2025, and -$1.8 million in Q2 2025.